Clinical TrialApr 21, 2026, 10:41 AM
Black Diamond to Present Silevertinib Data at ASCO 2026
AI Summary
Black Diamond Therapeutics announced multiple presentations for its MasterKey therapy, silevertinib, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations will include an oral session on Phase 2 data for silevertinib in treatment-naïve NSCLC patients with non-classical EGFR mutations. Additionally, two poster sessions will cover Phase 2 data in previously treated NSCLC and a trial-in-progress for newly diagnosed EGFRvIII-positive glioblastoma (GBM).
Key Highlights
- Black Diamond to present three updates on silevertinib at ASCO 2026.
- Oral presentation on Phase 2 data for silevertinib in treatment-naïve NSCLC.
- Poster presentation on Phase 2 data for silevertinib in previously treated NSCLC.
- Poster on trial-in-progress for Phase 2 silevertinib in newly diagnosed GBM.
- Prior data showed 60% ORR and 86% CNS ORR for silevertinib in frontline NSCLC.
Price Impact
More from BDTX